Abrocitinib and Digoxin (Digoxin Berk 0.25 mg): interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
P-glycoprotein inhibition can increase digoxin exposure.
Clinical significance and safety
Digoxin Berk 0.25 mg contains digoxin, a P-glycoprotein substrate with a narrow therapeutic window. Abrocitinib can increase exposure to susceptible P-glycoprotein substrates; the prescriber may need concentration monitoring or a regimen review. Nausea, visual symptoms or rhythm disturbances merit prompt assessment rather than self-adjustment.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.